Tenax Therapeutics faces class action lawsuit over securities disclosures
Shareholder rights firm Robbins LLP has initiated a class action lawsuit against Tenax Therapeutics, alleging misrepresentation of company performance and regulatory status.
A class action lawsuit has been filed against Tenax Therapeutics, Inc. (NASDAQ: TENX) following allegations that the company provided misleading information to investors. The litigation covers individuals and entities that acquired company securities between November 13, 2023, and the present.
The complaint centers on claims that the biotechnology firm failed to disclose material information regarding the clinical prospects or regulatory pathway of its product candidates. Plaintiffs argue these omissions led to an artificial inflation of the stock price, resulting in financial losses when subsequent information reached the market.
Legal representatives are currently evaluating the impact of these disclosures on shareholder value. The lawsuit seeks to hold the company accountable for damages incurred by investors during the specified period.
Tenax Therapeutics has not yet filed a formal response to the allegations in court. Investors are currently being notified of their rights to participate in the pending legal action.